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MicroRNA-21 (miR-21) is a key regulator of oncogenic
processes. It is signiﬁcantly elevated in the majority of
human tumors and functionally linked to cellular prolifera-
tion, survival and migration. In this study, we used two
experimental-based strategies to search for novel miR-21
targets. On the one hand, we performed a proteomic
approach using two-dimensional differential gel electro-
phoresis (2D-DIGE) to identify proteins suppressed upon
enhanced miR-21 expression in LNCaP human prostate
carcinoma cells. The tumor suppressor acidic nuclear
phosphoprotein 32 family, member A (ANP32A) (alias
pp32 or LANP) emerged as the most strongly down-
regulated protein. On the other hand, we applied a
mathematical approach to select correlated gene sets that
are negatively correlated with primary-miR-21 (pri-miR-21)
expression in published transcriptome data from 114 B-cell
lymphoma cases. Among these candidates, we found tumor
suppressor SMARCA4 (alias BRG1) together with the
already validated miR-21 target, PDCD4. ANP32A and
SMARCA4, which are both involved in chromatin remodel-
ing processes, were conﬁrmed as direct miR-21 targets by
immunoblot analysis and reporter gene assays. Further-
more, knock down of ANP32A mimicked the effect of
enforced miR-21 expression by enhancing LNCaP cell
viability, whereas overexpression of ANP32A in the
presence of high miR-21 levels abrogated the miR-21-
mediated effect. In A172 glioblastoma cells, enhanced
ANP32A expression compensated for the effects of anti-
miR-21 treatment on cell viability and apoptosis. In
addition, miR-21 expression clearly increased the invasive-
ness of LNCaP cells, an effect also seen in part upon
downregulation of ANP32A. In conclusion, these results
suggest that downregulation of ANP32A contributes to the
oncogenic function of miR-21.
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Introduction
MicroRNAs (miRNAs) are short non-coding RNAs
involved in post-transcriptional regulation of gene
expression. They originate from mRNA-like, long
primary transcripts (pri-miRNA) that are processed by
two sequential cleavage steps into their mature form.
In animals, miRNAs bind to partly complementary
sequences located predominantly within the 30 untrans-
lated regions and mediate translational repression or
degradation of their target mRNAs (Bartel, 2004). More
than 700 human miRNAs have been identiﬁed to date
and proteome-wide studies suggested that an individual
miRNA can regulate hundreds of targets (Baek et al.,
2008; Selbach et al., 2008; Yang et al., 2010). They have
been found to play an important role in fundamental
cellular processes, including proliferation, apoptosis,
migration and differentiation. Hence, aberrant miRNA
expression has been correlated and functionally linked
to cancerogenesis (Calin et al., 2002; Garzon et al.,
2009).
MicroRNA-21 (miR-21) stands out as the only
miRNA overexpressed in the vast majority of cancer
types analyzed (Krichevsky and Gabriely, 2009). Ele-
vated levels have been demonstrated in solid tumors of,
for example, breast, lung, colon, pancreas, prostate,
liver, stomach and brain, as well as in hematological
cancers, including chronic lymphocytic leukemia, diffuse
large B-cell lymphoma (DLBCL) and Hodgkin lympho-
ma (Chan et al., 2005; Iorio et al., 2005; Volinia et al.,
2006; Fulci et al., 2007; Lawrie et al., 2007; Navarro
et al., 2008). Direct evidence for the oncogenic potential
of miR-21 was revealed by functional studies in several
cancer cell lines. Knock down of miR-21 was shown to
cause increased apoptosis and reduced invasiveness in
glioblastoma (Chan et al., 2005), reduced cell prolifera-
tion in breast and cervix cancer (Frankel et al., 2008;
Zhu et al., 2008; Yao et al., 2009), as well as decreased
cellular invasion and metastasis in colorectal cancer
(Asangani et al., 2008). Conversely, miR-21 overexpres-
sion resulted in increased tumor cell proliferation,
migration and invasion in hepatocellular carcinoma, as
well as chemoresistance of cholangiocarcinoma (Meng
et al., 2006). Recent work of our group demonstrated
that signal transducer and activator of transcription 3
induces pri-miR-21 transcription, and elevation of
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myeloma (Lofﬂer et al., 2007). Therefore, understanding
the network of miR-21-induced gene expression changes
is of fundamental interest.
To date, experimentally conﬁrmed targets include
multiple tumor suppressive components of the p53,
TGF-b and mitochondrial apoptosis pathways (Papa-
giannakopoulos et al., 2008), as well as tumor suppres-
sors PDCD4 (Asangani et al., 2008), PTEN (Meng
et al., 2007), RECK (Gabriely et al., 2008), TPM1 (Zhu
et al., 2008) and Maspin (Zhu et al., 2008).
The identiﬁcation of mRNAs targeted by a particular
miRNA has been a great challenge because of the only
partial complementarity between miRNAs and their
targets. Much of the early efforts based on computa-
tional algorithms combined continuous pairing of
6–8 bases in the 50 miRNA seed region and the
30 untranslated region of mRNAs with phylogenetic
conservation of the complementary sequence in the
30 untranslated region of orthologous genes (Lewis et al.,
2003; Kiriakidou et al., 2004; John et al., 2006).
However, about 30% of the predicted mRNA target
sites cannot be validated experimentally (Martin et al.,
2007) and more than one quarter of experimentally
validated miRNA targets are not predicted by any of
the most commonly used miRNA target prediction
programs (Sethupathy et al., 2006). As miRNAs can
regulate both mRNA stability and protein synthesis,
experimental approaches include gene expression ana-
lysis and proteomic screening.
In this study, we searched for novel miR-21 targets
applying both strategies. We analyzed LNCaP cells
transfected with miR-21-expressing or -control vectors
by two-dimensional differential in gel electrophoresis
(2D-DIGE). Furthermore, we used the statistical
analysis of B-cell lymphoma gene expression data by
searching for genes inversely correlated with high pri-
miR-21 levels. On the basis of these results, we
demonstrate that tumor suppressors ANP32A and
SMARCA4 are direct targets of miR-21. Furthermore,
we provide experimental evidence that ANP32A is able
to contribute to various miR-21-mediated effects.
Results
Identiﬁcation of putative miR-21 targets by use
of 2D-DIGE
In order to identify putative miR-21 targets, a global
proteomic approach using DIGE was conducted with
samples from cells expressing different miR-21 levels.
Recent studies have shown that miR-21 is upregulated
in prostate cancer cells (Volinia et al., 2006) and that its
expression in prostate cancer cell lines rises with the
grade of androgen-independence and malignancy from
LNCaP to PC-3 and DU-145 cells (Li et al., 2009). We
chose LNCaP cells that express very low levels of miR-
21 for transfection with either a pre-miR-21-expressing
plasmid or an empty vector and searched for proteins
regulated by enhanced miR-21 expression. As measured
by quantitative PCR, miR-21 levels were raised to about
two- to threefold compared with the control (data not
shown). Cells were lysed and proteins were ﬂuorescence-
labelled, 24h after transfection. After co-separating the
protein extracts and ﬂuorescence scanning, differentially
expressed spots were detected (Figure 1). In summary,
37 protein spots displayed an at least 1.3-fold regulation
over three independent experiments. Among the 25
proteins unambiguously identiﬁed by mass spectro-
metry, 5 proteins were represented by two or more
spots exhibiting a comparable ratio of expression that
were most likely caused by post-translational modiﬁca-
tion (Supplementary Table 1). Using an at least 1.5-fold
differential regulation and a P-value of p0.05 as cut-
offs, we found 16 proteins that were all suppressed in the
presence of miR-21 (Table 1 and Supplementary Figure
1). This overall downward direction in regulated spots is
consistent with the concept of miRNA-mediated trans-
lational inhibition.
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Figure 1 Identiﬁcation of putative miR-21 target genes in LNCaP
cells by 2D-DIGE. LNCaP cells were transfected with either empty
or miR-21 expression vectors, harvested after 24h, and protein
lysates were labeled with Cy3 or Cy5 (miR-21 and control) and Cy2
for the internal standard. (a) Representative gel image obtained
after isoelectric focussing at pH 3–10, followed by separation in a
12% SDS–polyacrylamide gel. Numbers indicate spots identiﬁed as
differentially expressed. (b) Enlarged area maps of spot 28
(corresponding to ANP32A) obtained by separate Cy3 (miR-21)
and Cy5 (control) evaluation. The bar chart shows the relative
expression level of ANP32A protein in cells transfected with
miR-21 or control.
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OncogeneBioinformatical screening of the 16 candidate
mRNAs for miR-21 target sequences by programs
requiring a perfect seed match were not successful. By
applying the RNA22 tool (Huynh et al., 2006), which
allows G:U pairing of the target mRNA to the miRNA
seed sequence, we obtained perfect 7-mer seed matches
for LTA4H, RPSA, EIF3I, CSDE1 and HDLBP
(Supplementary Figure 2a). With regard to cellular
function, the majority of proteins listed in Table 1 play a
role in biosynthetic and metabolic processes. This is
likely because of the fact that many proteins with basal
cellular functions show rather high expression levels,
which favor their identiﬁcation by DIGE. Notably, ﬁve
of them (DDX3X, CSDE1, EIF5A, HDLBP and NCL)
are RNA-binding proteins. Among the candidates,
tumor suppressor ANP32A showed the strongest down-
regulation (4.3-fold; Figure 1b).
Identiﬁcation of putative miR-21 targets by applying
statistics on gene expression data
In parallel, we used a mathematical approach based on
the analysis of published gene expression data to
identify further putative miR-21 targets. We took
advantage of the fact that the affymetrix U133A
expression array contains a probe set detecting pri-
miR-21. The human MIR21 gene overlaps with protein-
coding gene TMEM49 (transmembrane protein-49)
(Figure 2a), but is independently transcribed from a
conserved promoter residing within an intron of
TMEM49 (Lofﬂer et al., 2007; Fujita et al., 2008). The
pri-miR-21 transcript has been shown to be both capped
and polyadenylated (Cai et al., 2004), suggesting its
labeling by gene expression proﬁling using oligo (dT)
priming. As shown in Figure 2, the Affymetrix U133A
GeneChip exhibits a probe set detecting both TMEM49
and pri-miR-21. For both genes, no other (speciﬁc)
probe set exists on U133A.
U133A gene expression data of 114 B-cell lymphomas
from Hummel et al. were used for statistical analysis
(Hummel et al., 2006). On the basis of their expression
signatures, 25 out of 114 cases have been classiﬁed as
Burkitt’s lymphomas. The other cases correspond to the
group of DLBCL that can be molecularly subclassiﬁed
into germinal center B cell-like and activated B cell-like
DLBCL types, with some cases remaining unclassiﬁed
(Rosenwald et al., 2002). Pri-miR-21 showed signiﬁcant
higher expression levels in the DLBCL subgroups than
in Burkitt’s lymphomas (Figure 2b). Assuming that the
amplitude of pri-miR-21 transcription reﬂects the level
of mature miR-21, mRNAs suppressed in the presence
of high pri-miR-21 (and TMEM49) expression might
represent putative miR-21 targets. To search for genes
negatively correlated with the pri-miR-21 probe set, we
applied a recently published multivariate procedure for
the analysis of gene expression data (Lauter et al., 2009).
This algorithm searches for gene sets that show a
correlated expression within gene expression studies.
Applying such correlated gene sets instead of single
genes leads to increased power and stability of statistical
analyses. After retrieving all correlated gene sets from
the lymphoma expression data, we searched for gene
sets exhibiting negative correlation to pri-miR-21. As a
result, we obtained four gene sets comprising eight genes
on a signiﬁcance level of 0.01 (Table 2). Remarkably,
one of the most frequently validated miR-21 targets,
PDCD4, was among the identiﬁed genes supporting the
reliability of the approach. As expected, opposite to the
pri-miR-21 levels, putative miR-21 target genes are
expressed higher in Burkitt’s lymphomas than in
DLBCL (Figure 2c).
Among these candidates, DNMT1, METAP2 and
TCF3 exhibit perfect 7-mer seed matches that include
G:U pairing (Supplementary Figure 2b). Five out of
eight candidates are involved in transcriptional regula-
tion (SSBP2, SMARCA4, PDCD4, DNMT1 and
TCF3). Furthermore, PPP2R3B, SSBP2, SMARCA4
and PDCD4 have been described in the context of
tumor suppression, which remarkably agrees with the
Table 1 Putative targets of miR-21 identiﬁed by 2D-DIGE
Gene symbol
a Protein name Ratio
b P-value
ANP32A Acidic nuclear phosphoprotein 32 family, member A 0.23 0.025
ME1 NADP-dependent malic enzyme 0.25 0.047
NCL Nucleolin 0.44 0.012
LTA4H Leukotriene A4 hydrolase 0.44 0.005
PEBP1 Phosphatidylethanolamine-binding protein 1 0.58 0.050
SOD1 Superoxide dismutase 1 0.58 0.0002
RPSA 40S ribosomal protein SA 0.59 0.002
EIF5A Eukaryotic translation initiation factor 5A 0.59 0.035
ATP6V0D1 Vacuolar proton-ATPase, subunit D 0.59 0.004
GNB2L1 Guanine nucleotide-binding protein subunit beta-2-like 1 0.61 0.011
HADHA Trifunctional enzyme subunit alpha 0.61 0.003
DDX3X X-linked DEAD box protein 3 0.61 0.013
EIF3I Eukaryotic translation initiation factor 3 subunit I 0.64 0.016
CFL1 Coﬁlin-1 0.65 0.016
CSDE1 Cold shock domain-containing protein E1 0.65 0.003
HDLBP High-density lipoprotein-binding protein 0.65 0.023
Abbreviations: miR-21, microRNA-21; 2D-DIGE, two-dimensional differential in gel electrophoresis.
aGene symbols following UniProtKB.
bExpression level (miR-21 versus control).
For proteins identiﬁed by several spots, results with the lowest P-values are shown.
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SMARCA4 (also known as BRG1) was found included
in two different gene sets (Table 2).
Remarkably, when the four gene sets were used to
cluster the cohort of 114 lymphoma cases, not only the
Burkitt’s lymphomas cases clustered into one group
but also the activated B cell-like and germinal center B
cell-like subgroups of DLBCL were almost perfectly
separated (Figure 2c). Therefore, although the expres-
sion of pri-miR-21 appears comparable in activated B
cell-like and germinal center B cell-like (see above), its
molecular targets might differ between these two
DLBCL subgroups. This suggests that the function of
miR-21 might depend on the cellular context.
Tumor suppressors ANP32A and SMARCA4 are both
downregulated by miR-21
From the two approaches to identify miR-21 targets,
ANP32A and SMARCA4 were selected for further
conﬁrmation on the basis of their common implication
in cancerogenesis and chromatin remodeling. First, we
studied their miR-21-mediated negative regulation by
immunoblot analysis in cell lines of various origins.
Depending on the endogenous miR-21 levels, being
either low (LNCaP prostate carcinoma, HEK293
embryonic kidney cells) or high (DU-145 prostate
carcinoma, SU-DHL-2 DLBCL), we used miR-21
precursors or anti-miR-21 to enhance or reduce the
cellular miR-21 levels, respectively. For DU-145, both
strategies were performed. Transfection of miR-21
precursors elevated the miR-21 level about 2.5-fold in
DU-145, 10-fold in LNCaP and 20-fold in HEK293
cells. The reduction of the miR-21 levels by anti-miR-21-
oligonucleotides was conﬁrmed by a miR-21-sensitive
reporter assay resulting in a twofold increase of the
luciferase activity (data not shown). As displayed in
Figure 3, overexpression (a) and knock down (b) of
miR-21 revealed the corresponding vice versa effects on
ANP32A protein expression in all four cell lines. The
same was true for SMARCA4, with the exception that
this protein was not detectably expressed in DU-145.
Concluding from these results, ANP32A and SMAR-
CA4 protein levels correlate inversely with miR-21
expression.
ANP32A and SMARCA4 are direct targets of miR-21
To test whether ANP32A and SMARCA4 are directly
regulated by miR-21, we searched both mRNA
sequences for predicted miR-21-binding sites using
RNA22. By allowing mismatch pairing of the target
mRNA to the miRNA seed sequence compensated by 30
matches, a putative miR-21 complementary region in
the ANP32A sequence (nt901–920 of NM_006305) and
SMARCA4 (nt5247–5268 of NM_001128849) were
found (Figure 4a). These target sites show a high
interspecies homology in mammals (Figure 4b). For
ANP32A, whose target site overlaps the open reading
frame, this conservation includes the wobble bases
putatively forming the miR-21–mRNA interaction. We
constructed reporter genes containing a 213bp sequence
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Figure 2 Analysis of pri-miR-21 expression in B-cell lymphomas.
(a) Schematic representation of the human MIR21 gene locus that
overlaps with the last two exons of the TMEM49 gene on
chromosome 17. Affymetrix probe set 220990_at detects TMEM49
as well as pri-miR-21. The black line within the pri-miR-21 bar
indicates the location of mature miR-21 sequence. (b) Box plot
showing the expression of pri-miR-21 in gene expression data from
114 lymphomas (Hummel et al., 2006) grouped into molecular
Burkitt’s lymphoma (mBL) and in DLBCL subgroups GCB
(germinal center B cell-like), ABC (activated B cell-like), and in
DLBCL samples that cannot be assigned to either subgroup
(unclassiﬁed). The P-values shown are not adjusted for multiple
testing, but remain signiﬁcant after adjusting with the Bonferroni
method for the six possible pairwise tests. (c) In gene expression
data from the lymphomas cases above, correlated sets of genes were
retrieved and spatially sorted according to a previously published
procedure (Lauter et al., 2009). In the heat map, lymphoma cases
and the four gene sets negatively correlated to pri-miR-21
expression were arranged that neighboring cases (columns) and
neighboring gene sets (rows) are correlated as highly as possible.
Data of 43 cases with low spatial information for the circular data
representation were excluded. The largest gap between the cases
and between the gene sets marks the beginning and the end of the
ordered case and gene-set sequence, respectively. The heat map
illustrates the expression of the eight putative miR-21 target genes
belonging to the four identiﬁed gene sets. Light and dark gray
indicate high and low expression, respectively.
ANP32A and SMARCA4 are targets of microRNA-21
K Schramedei et al
2978
Oncogeneof ANP32A starting 22 nucleotides 50 of the stop codon
and the entire 30 untranslated region of SMARCA4
downstream of the luciferase gene. A reporter construct
containing three successive miR-21-binding sites was
used as positive control. The reporter plasmids were
transfected into LNCaP cells along with pre-miR-21 or
a precursor control, and luciferase activity was deter-
mined. Enhanced expression of miR-21 signiﬁcantly
reduced reporter activity of both constructs to about
70% compared with the control (Figure 4c, left panel).
We next mutated the reporter constructs by altering
bases in the predicted miR-21 target sequences
(Figure 4a). These mutations abolished the suppressive
effect of pre-miR-21 on the luciferase activity of the
ANP32A and SMARCA4 constructs (Figure 4c, right
panel), verifying the functionality of the putative
binding sites. Taken together, our results indicate that
ANP32A and SMARCA4 are direct targets of miR-21.
ANP32A contributes to the transformation promoting
effects of miR-21
miR-21 has been demonstrated to support tumor cell
growth and invasion. Therefore, we next investigated
the proliferative effect of miR-21 in LNCaP prostate
cancer cells. As determined after 5 days, enhanced
miR-21 expression almost doubles the cell number
compared with cells transfected with the control
precursor (Figures 5a and b). To investigate the
biological importance of ANP32A in the miR-21 target
network, we studied whether ANP32A inﬂuences the
proliferation of LNCaP cells. For this purpose, we
performed a knock down of ANP32A protein (Supple-
mentary Figure 3) and determined the cellular metabolic
activity reﬂecting the number of viable cells. Lowering
the ANP32A protein level by RNA interference raised
the LNCaP cell number to the same level as obtained by
enhanced miR-21 expression (Figure 5a). Conversely, a
high ANP32A protein level abrogated the miR-21-
mediated effect on cell viability (Figure 5b). Further-
more, we analyzed whether ANP32A could also
contribute to the miR-21-induced effects on cells of
different origins exhibiting high miR-21 levels. For the
glioblastoma cell line A172 it has been shown that
reduction of endogenous miR-21 level causes a sig-
niﬁcant drop in cell number (Chan et al., 2005). In our
hands, anti-miR-21-oligonucleotides reduced cell viabi-
lity to about 70% and increased the pro-apoptotic
caspase activity to 130%. Enhanced ANP32A expres-
sion mimicked these miR-21-induced effects (Figures 5c
and d). To study the effect of miR-21 on the migra-
tion potential of LNCAP cells, we used the Matrigel
Invasion Assay. Cells were transfected with pre-miR-21
or ANP32A-speciﬁc small-interfering RNA and the
corresponding controls. After 48h, cells were seeded in
the invasion chambers for 20h. Afterwards, LNCaP
cells that passed the matrigel were stained and counted.
As shown in Figure 5e, enhanced miR-21 expression
increased the number of migrated cells more than
threefold. ANP32A knockdown by RNA interference
also led to a signiﬁcant higher cell invasion, but did not
reach the miR-21-induced level. Taken together, these
results suggest that ANP32A accounts for the various
biological effects of miR-21 in different cell types.
With regard to SMARCA4, knockdown experiments
in LNCaP and SUDHL-2 cells did not reveal an
increase of cellular viability (data not shown).
Discussion
miRNAs have emerged as important post-transcrip-
tional regulators of gene expression. By inﬂuencing the
Table 2 Putative targets of miR-21 identiﬁed by gene set analysis of gene expression data from B-cell lymphomas
Gene set P-value Gene number Gene symbol Gene name
A 0.002 1 PPP2R3B Protein phosphatase 2 (formerly 2A), regulatory subunit B, b
B 0.004 2 SSBP2 Single-stranded DNA-binding protein 2
SMARCA4 SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin,
subfamily a, member 4
C 0.004 2 PDCD4 Programmed cell death 4 (neoplastic transformation inhibitor)
NCRNA00081 Non-protein coding RNA 81
D 0.004 4 SMARCA4 SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin,
subfamily a, member 4
DNMT1 DNA (cytosine-5-)-methyltransferase 1
METAP2 Methionyl aminopeptidase 2
TCF3 Transcription factor 3
Abbreviation: miR-21, microRNA-21.
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Figure 3 ANP32A and SMARCA4 are regulated by miR-21 in
various cell lines. Prostate cancer (LNCaP, DU-145), DLBCL (SU-
DHL2), or embryonic kidney (HEK293) cells were transfected with
miR-21 or control precursor (a) or with anti-miR-21 or control
LNA (b). Cell lysates were prepared and immunoblot analysis of
ANP32A and SMARCA4 was performed 72h post transfection.
Numbers indicate quantiﬁcation relative to the corresponding
b-actin loading control.
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Oncogeneexpression of multiple target genes simultaneously,
miRNAs function as dimmer switches by ﬁne-tuning
the gene expression patterns and comprise the potential
of complex changes in cellular physiology. Among them,
miR-21 has been shown to be a key regulator of
oncogenic processes (Selcuklu et al., 2009).
We applied two experimental-based strategies to
identify novel miR-21 targets. With a proteomic
approach, we identiﬁed 16 proteins either directly or
indirectly suppressed by enhanced miR-21 expression in
LNCaP prostate cancer cells. None of these novel
candidates was found by target site prediction algo-
rithms requiring the presence of a perfect miRNA seed
match. This ﬁnding is consistent with the results
obtained by Yang et al. on miR-21 targets in breast
cancer cells, ﬁnding that less than 10% proteins
identiﬁed by a proteomic approach were predicted by
Pictar, Targetscan and miRanda (Yang et al., 2009).
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5´UAUUUAUACAG-CAGAGAAGCUGUAG 3´
UAUUUAUACAG-CAGAGAAGCUGUAG
UAUUUAUACAG-CCGAGAAGCUGUAG
CAUUUUUA-GG-CAGAGAAG-UAUAG
UAUUUAUACUG-CAGAGAAGAUGUAG
UAUUUAUACGG-CAGAGAAGAUGUAG
Canislupusfamiliaris  GAGGGAGAAGA-CGAUGA-CUAAGU
D D G E/G STOP
UAUUUAUACGG-CAGAGAAGAUGUAG
D/E E/D
ANP32A 900-1112
SMARCA4 3'UTR
positive control
vector
vector
ANP32A 900-1112
ANP32A mut915-920
SMARCA4 3'UTR
SMARCA4 mut5263-5267
p = 0,008
Figure 4 ANP32A and SMARCA4 are direct targets of miR-21. (a) Putative miR-21-binding sites within ANP32A (NM_006305) and
SMARCA4 (NM_001128849) genes. Perfect matches are indicated by a line; G:U pairs by a colon. The frame marks nucleotides
mutated for the reporter gene assays. (b) Comparison of nucleotides between the miR-21 sequence and its targets in various species.
For the ANP32A site overlapping the open reading frame, amino acids are indicated. (c) Cloned ANP32A and SMARCA4sequences
are targeted by miR-21 (left panel), and mutation of the putative binding sites abolishes this effect to wild type level (right panel).
pMIR-REPORT vectors containing ANP32A-900-1112, SMARCA4-30 untranslated region (30UTR) and their mutated variants were
co-transfected with miR-21 or control precursor into LNCaP cells. A vector containing three miR-21-binding sites was used as a
positive control. Luciferase activity was assayed after 48h. Data are normalized to the corresponding control sample. Values are the
means±s.d. from six independent experiments. The P-values were determined using a two-tailed t-test.
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OncogeneNevertheless, ﬁve of our candidates possess a perfect
7-mer seed match when G:U pairing is allowed.
Furthermore, with the exception of Coﬁlin-1 (no hit),
all putative targets show between 1 and 3 hits out of ten
different algorithms searching for miRNA target sites
that are currently available by miRecords (mirecords.
biolead.org) (Xiao et al., 2009). For comparison, among
the 27 validated miR-21 targets listed in the miRecords
database (december 2010), the number of hits by these
ten algorithms ranges from 1 to 6. Furthermore, our
candidate DDX3X has also been identiﬁed by Yang
et al. (2009). These observations indicate that a majority
of direct candidates likely possess imperfect seed base
pairing supported by 30 compensatory target sites
(Brennecke et al., 2005), as shown for ANP32A and
SMARCA4 in this study.
Applying a multivariate procedure for searching
correlated gene sets in expression data from lymphoma
patients, we obtained a rather short list of eight genes
that show a signiﬁcantly lower expression in the
presence of a high pri-miR-21 level. This statistical
strategy acts on the assumption that ﬁnding gene sets
with correlated expression patterns increases the
probability of a biological signiﬁcant context. There
have been two concerns in using probe set 220990_s_at
for a miR-21 target gene search. The probe set does
not only detect pri-miR-21 but also the overlapping
gene TMEM49, and miR-21 levels might undergo a
post-transcriptional regulation. Nevertheless, the
presence of PDCD4, which was bioinformatically
predicted and experimentally conﬁrmed as a miR-21
target in several cell types (Asangani et al., 2008;
Frankel et al., 2008; Lu et al., 2008; Zhu et al., 2008;
Yao et al., 2009), strongly supports the reliability of our
approach.
We did not observe an overlap of both candidate lists,
which might result from the different nature of the
underlying mechanisms (mRNA destabilization or
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Figure 5 ANP32A contributes to the oncogenic potential of miR-21. MiR-21 precursor, ANP32A-speciﬁc small-interfering RNA
(siRNA) and an ANP32A-expressing plasmid as well as their corresponding controls were introduced into LNCaP and A172 cells, as
indicated. Afterwards, cell proliferation (a–c), caspase-3/7-activity (d), and Matrigel invasion (e) were assayed. For the latter,
representative pictures of the invaded cells (black colored) on the assay membrane were taken. Bar graphs represent mean values±s.d.
from three independent experiments.
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Oncogenetranslational inhibition) and from the different cell types
analyzed. A cell-type-speciﬁc target gene knockdown
would, for example, be the outcome of a synergistic
action of two or more differentially expressed miRNAs.
Moreover, the DIGE approach is limited to proteins of
intermediate to high abundance and favours the display
of proteins that separate apart from the bulk of other
proteins. In particular, SMARCA4 could not be
separated by DIGE because of its high molecular weight
of about 200kDa.
The direct regulation of ANP32A (from 2D-DIGE)
and SMARCA4 (from gene expression analysis) was
conﬁrmed by reporter gene assays. Both proteins were
found to be negatively correlated with miR-21 levels, for
example, downregulated by miR-21 overexpression and
upregulated by miR-21 inhibition in several cell lines. In
addition to RNA22, miR-21 target sequences in
ANP32A and SMARCA4 were also suggested by two
other prediction programs offered by miRecords (miR-
anda, RNAhybrid for ANP32A, and PITA, RNAhybrid
for SMARCA4). The putative miR-21 target sites show
an explicit interspecies conservation and mediate a
reduced reporter activity upon miR-21 overexpression.
Moreover, they were functionally characterized by
site-directed mutagenesis. Notably, the miR-21-binding
element in ANP32A overlaps the stop codon.
ANP32A has been identiﬁed in various molecular
contexts accounting for its numerous aliases: leucin-rich
acidic nuclear protein (Matsuoka et al., 1994), putative
HLA class II-associated protein I (Vaesen et al., 1994),
inhibitor-1 of protein phophatase-2A (Li et al., 1995,
1996), phosphoprotein 32 (Chen et al., 1996) and
Mapmodulin (Ulitzur et al., 1997). Hence, ANP32A is
a multifunctional protein and involved in diverse
biological events. Its tumor suppressive function is
based on both cancer pathology analysis (Brody et al.,
2007; Hoffarth et al., 2008) and functional studies
demonstrating that overexpression of ANP32A inhibits
oncogene-mediated transformation (Chen et al., 1996;
Brody et al., 1999; Bai et al., 2001). Functions of
ANP32A that might be related to its tumor suppressive
activity are the inhibition of protein phosphatase 2A
(Li et al., 1996) and histone acetyltransferases (Seo et al.,
2001), as well as the stimulation of apoptosis by caspase
activation (Pan et al., 2009). By being a part of the
inhibitor of histone acetyltransferases complex,
ANP32A is involved in modulating chromatin structure
and transcriptional regulation (Seo et al., 2001). Inter-
estingly, in addition to ANP32A, inhibitor of histone
acetyltransferases contains isoforms A and B of the SET
protein that belongs to the extended candidate list of
putative miR-21 targets obtained by 2D-DIGE (Supple-
mentary Table S1) and also possesses miR-21-binding
sites as predicted by miRecords. Therefore, our results
indicate that miR-21 suppresses the function of the
inhibitor of histone acetyltransferases complex.
SMARCA4 is the catalytical component of the SWI/
SNF chromatin-remodeling complex that regulates gene
expression by disrupting histone–DNA contacts in an
ATP-dependent manner (Khavari et al., 1993). It acts in
association with many transcription factors by inducing
an open state of the nucleosome (Reisman et al., 2009).
There are some observations proposing SMARCA4 as a
tumor suppressor. SMARCA4-heterozygous mice have
an increased predisposition to tumor development
(Bultman et al., 2000). Furthermore, the SMARCA4
gene is frequently silenced in cancer (Reisman et al.,
2009; Rodriguez-Nieto and Sanchez-Cespedes, 2009)
and its ectopic expression induces tumor cell growth
arrest (Dunaief et al., 1994).
miR-21 promotes several transformation parameters
in tumor cells derived from various origins (Meng
et al., 2007; Frankel et al., 2008; Yao et al., 2009).
In agreement with published data, we found that high
miR-21 levels increase tumor cell viability and migration
as well as inhibit pro-apoptotic caspase activity. We
show that these effects can be mimicked by the
respective manipulation of ANP32A expression. These
data suggest that ANP32A is part of the network of
miR-21 target genes that increase the transformational
potential of cells. As for SMARCA4, the vast majority
of experiments demonstrating its tumor suppressing
activity were performed in cells lacking SMARCA4
expression (Strober et al., 1996; Wong et al., 2000).
In agreement with our results, neither enhanced
proliferation nor decreased apoptosis have been demon-
strated upon application of SMARCA4-speciﬁc small-
interfering RNA in the literature to date. In contrast, in
normal mammary epithelial cells, SMARCA4 knock-
down even inhibited cell proliferation (Cohet et al.,
2010). Given the fundamental function of SMARCA4 in
cellular transcription, the precise cellular context leading
to its tumor suppressive effect remains to be elucidated.
Taken together, previous reports along with the
identiﬁcation of ANP32A and SMARCA4 as novel
target genes indicate that miR-21 acts as key oncomiR
by favouring neoplastic transformation on multiple
levels. Understanding these gene networks could allow
the development of new approaches for cancer diagnosis
and therapy.
Materials and methods
Cell culture and reagents
Prostate carcinoma cell lines LNCaP and DU-145 (both from
DSMZ, Braunschweig, Germany) and DLBCL cell line
SUDHL-2 (from R Dalla-Favera, New York, NY, USA)
were maintained in RPMI 1640. HEK293 and glioblastoma
A172 cells were cultivated in Dulbecco0s modiﬁed Eagle0s
medium. All media were supplemented with 10% fetal calf
serum (FCS) and 100U/ml of penicillin and streptomycin
(Invitrogen, Karlsruhe, Germany). Antibodies against
ANP32A (sc-5652) and SMARCA4 (sc-17796) were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-
b-actin (Clone AC-74) antibody was from Sigma (Taufkirchen,
Germany). Precursor molecules for miR-21 and controls were
purchased from Ambion (Applied Biosystems, Darmstadt,
Germany), antisense and control oligonucleotides (miRCURY
LNA knockdown) for miR-21 knockdown were from Exiqon
(Vedbaek, Denmark). Validated small-interfering RNA
against ANP32A and control (AllStars Negative Control
siRNA) was taken from Qiagen (Hilden, Germany).
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The pre-miR-21 expressing vector (pSuper-miR21) has been
described previously (Lofﬂer et al., 2007). Empty control
vector or pSuper-miR21 was introduced into LNCaP cells
using Amaxa Nucleofector II Device with Kit R and program
T-09, according to the manufacturer’s protocol (Lonza,
Cologne, Germany). Transfection efﬁciency over 80% was
monitored by EGFP coexpression. After 24h, cells were
washed with phosphate buffered saline and 10mM Tris (pH
8.0) containing 5mM magnesium acetate. Subsequently, cells
were harvested in cell lysis buffer (20mM Hepes pH 7.2, 10%
glycerol, 1% Triton X-100, 1mM EDTA, 0.5% protease
inhibitor cocktail (Sigma P8340), 1.25% Benzonase (Merck,
Darmstadt, Germany)).
Labeling of the samples was performed following manufac-
turer’s instructions (GE Healthcare, Buckinghamshire, UK).
Brieﬂy, cellular proteins were precipitated, resuspended in
labeling buffer and aliquots stained by different ﬂuorescent
cyanine dyes. Samples were pooled, mixed with rehydration
solution and applied to a rehydration tray. Separation in a
two-dimensional gel and further processing was performed as
described (Morbt et al., 2009). In short, immobilized pH
gradient (IPG) strips were rehydrated overnight, after focusing
equilibrated, and subsequently alkylated. Strips were then
placed on acrylamide gels. Directly after the run, gels were
scanned and dried between cellophane sheets. Images of the
DIGE gels were quantitatively analyzed using Delta 2D
software (Decodon GmbH, Greifswald, Germany). Differen-
tially expressed proteins were identiﬁed using the following
parameters: expression ratio lower than 0.75 or higher than
1.35 and a P-value of Po0.05, as obtained by the software’s
integrated Student’s t-test. Proteins of interest were cut from
dried gels and identiﬁed by mass spectrometry. Tryptic
digestion was carried out with porcine trypsin as described
by Santos et al. (2007). Identiﬁcation of the extracted peptides
was done by using a Bruker Ultraﬂex III (Bruker Daltonik,
Bremen Daltonik, Bremen, Germany) or by reversed-phase
nano-LC and a tandem mass spectrometry mass spectrometer
(Jehmlich et al., 2008). Database searches were carried out
using the MS/MS ion search (MASCOT, http://www.matrixs-
cience.com) against all entries of the Swiss-Prot database
(http://www.expasy.org). Proteins were speciﬁed as unambigu-
ously identiﬁed, if the Mowse score was higher than 100 and at
least two different peptides (Po0.05) were used for identiﬁca-
tion. Molecular weight and pI of the identiﬁed protein were
cross-checked with the gel position of the excised spot.
Statistical analysis of gene expression
Statistical analysis was performed on a published U133A gene
expression data set of 114 lymphoma cases (‘training data set’)
(Hummel et al., 2006). To avoid repeated gene nominations,
the given 22277 probe sets were condensed to 9580 different
genes. For the pairwise tests for differential expression of the
pri-miR-21 probe set 220990_s_at, we used the Mann–Whitney
U-test. To ﬁnd genes negatively correlated with 220990_s_at,
the procedure for searching essential sets of variables in high-
dimensional data described by Lauter et al. (2009) was applied.
For our particular application, the following program para-
meters were set: The sum of deviation squares of a gene must
be greater than 35, yielding 1284 genes remaining in the
analysis. Spearman rank correlation was used. Gene sets were
constructed under the condition that the rank correlation
between a source gene and a partner gene must be greater than
O0.55E0.74. Resampling was carried out with 500 random
permutations of the data. The multiple level of signiﬁcance was
a¼0.01. Negative, one-sided signiﬁcance test was applied. The
b-sums statistic of a gene set was calculated only from the three
highest b-values. Data clustering and visualization was
performed as described (Lauter et al., 2009).
RNA isolation and quantitative PCR
To conﬁrm the transfection efﬁciency of the pre-miR-21-
expressing plasmid or miR-21 precursor oligonucleotides,
RNA was isolated and miR-21 expression levels were
determined as described (Lofﬂer et al., 2007).
Western blot analysis
DU-145 and HEK293 were transfected with 2mM oligonucleo-
tides using the MicroPorator MP-100, according to manufac-
turer’s instructions (Invitrogen). Electroporation of SUDHL-2
and LNCaP was as above except that, for SUDHL-2 cells,
program O-17 was used. Cells were harvested 72h post
transfection in RIPA buffer. Aliquots (30mg) were separated
on a 10% SDS–polyacrylamide gel electrophoresis and
transferred to a Immobilon-P Transfer membrane (Millipore,
Schwalbach, Germany). Immunodetection was performed
using chemiluminescence (SuperSignal West Dura Extended
Duration Substrate, Thermo Scientiﬁc, Rockfort, IL, USA).
Construction of expression vectors
For reporter gene assays, sequences of ANP32A and
SMARCA4 containing the potential miR-21-binding sites
were PCR-ampliﬁed from LNCaP total cDNA and cloned
into the pMIR-Report vector (Ambion) using the forward
primers 50-TTTACTAGTGAGGGAGAAGATGATGAC-30
and 50-GCCCCGACATTCCAGTC-30, and the reverse pri-
mers 50-TTTAAGCTTTTTTATTCCACCCCCACC-30 and
50-GCGTTTTGTTGTTGGTTTAATT-30, respectively. Mu-
tations into the seed region of the putative miR-21-binding site
of pMIR-Report-30SMARCA4 were introduced using the
QuikChange site-directed mutagenesis kit (Agilent Technologies,
Bo ¨ blingen, Germany) using primer 50- CCATATTTATAC
AGCAGAGCCTAGGTAGGACTGTTTGTG-30. Mutagen-
esis of ANP32A was performed by an inverse PCR approach
with primers mut929-34_fwd 50-GAGTTTTGAAAAATTCC
TATTGTG-30 and mut929-34_rev 50-GAGATTCCACTTA
GTCATCATCT-30 as well as mut915-20_fwd 50-GAGAGTG
GAATAACCTATTTTGA-30 and mut915-20_rev: 50-GAGT
CATCTTCTCCCTC-30. Mutations are underlined.
To construct a vector expressing ANP32A, a DNA frag-
ment covering the ANP32A coding region was ampliﬁed
from LNCaP cDNA by PCR using the forward primer
50-GCCGCCATGGAGATGGGCAGACGG-30 and reverse
primer 50-TTAGTCATCATCTTCTCC-30. After subcloning
the PCR fragment in pCR-Blunt II-Topo (Invitrogen),
sequence of ANP32A was released with XbaI/BamHI and
inserted into pCDNA3.1(þ) opened with NheI/BamHI.
miRNA target reporter assay
LNCaP cells were co-transfected with pMIR-Report vector
containing the sequences of ANP32A or SMARCA4 or their
mutated constructs, b-galactosidase vector for normalization
(0.5mg each) and miR-21 precursor or control (2mM) using
MicroPorator MP-100. The cells were lysed and reporter
activity was measured 48h post transfection using Luciferase
Assay System (Promega, Mannheim, Germany) and chemilu-
minescent b-Gal Reporter Gene Assay (Roche Diagnostics,
Mannheim, Germany).
Cell viability and caspase 3/7 assays
3000 LNCaP or 1000 A172 cells were seeded in 96-well plates
and transfected the following day using Lipofectamine 2000
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Oncogene(Invitrogen) or FuGENE HD Transfection Reagent (Roche
Diagnostics), respectively. Oligonucleotides were used with a
ﬁnal concentration of 100nM. For overexpression of ANP32A,
0.4mg (LNCaP) or 0.2mg (A172) plasmid were transfected per
well. Five days post transfection, the CellTiter-Glo Lumines-
cent Cell Viability Assay or Caspase-Glo 3/7 Assay (Promega)
was performed.
Invasion assay
LNCaP cells were co-transfected with miR-21 precursor,
siANP32A or control (2mM) using MicroPorator MP-100.
After 2 days of cultivation, cells were transferred into invasion
chambers (BD Biosciences, Heidelberg, Germany) containing
a matrigel-coated membrane of 8mm pore size. 10% FCS as
chemoattractant was added only to the lower compartment.
After incubation for 20h, the non-invaded cells were removed
from the upper surface of the membrane by a cotton swab. The
invaded cells were ﬁxed using methanol, stained by Toluidine
blue and counted per membrane.
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